Trial Profile
A Multi-Arm Phase III Trial Investigating HS-110 in Combination with Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 May 2021
Price :
$35
*
At a glance
- Drugs Viagenpumatucel-L (Primary) ; Checkpoint kinase inhibitors
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors NightHawk Biosciences
- 12 May 2021 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2021.
- 29 May 2020 According to an Heat Biologics media release, the company is planning an end-of-phase 2 meeting with the FDA to discuss registration trial design.
- 18 Apr 2018 According to a Heat Biologics media release, company plans to initiate this trial in Q3 2019.